Las Vegas runs on a schedule that doesn’t look like most cities’ — casino floors, hospitality shifts, and entertainment venues that operate long past midnight. Mental health care here has to work around that rhythm, which is part of why Spravato® (esketamine) fits well into our Henderson and Summerlin locations: it’s an FDA-approved, in-office treatment for depression that hasn’t responded to standard antidepressants, and it doesn’t require the multi-week ramp-up that oral medications typically demand before patients notice a difference.
Rather than nudging serotonin or norepinephrine the way most antidepressants do, Spravato works on NMDA receptors inside the brain’s glutamate system. It’s prescribed to be taken alongside an existing oral antidepressant, not as a replacement for it, and that combination is what’s associated with the quicker symptom relief some patients experience. Our Las Vegas clinical team tracks each patient’s response closely and fine-tunes the dosing from there.
Spravato falls under the FDA’s REMS program, a set of federal requirements built around risk management: certified facilities only, direct supervision by a licensed provider during self-administration, and a mandatory two-hour observation window afterward to watch blood pressure, sedation levels, and any dissociative symptoms before discharge.
Between Henderson, Summerlin, and the Strip corridor, our scheduling approach leans into the fact that a lot of Las Vegas works nights, weekends, or rotating shifts. We try to fit appointment slots into that reality instead of assuming a standard nine-to-five. What doesn’t flex, however, is the rule against driving afterward — every patient needs a ride arranged before their appointment, no exceptions.
As the Las Vegas Valley continues to grow, so does demand for treatment options beyond standard antidepressants — our clinics offer Spravato as an FDA-regulated addition to care for residents who haven’t found sufficient relief elsewhere. Treatment areas include:
That first visit is thorough by design: a detailed look at your psychiatric and medical background so our team can confirm candidacy and build a dosing schedule around your specific situation.
The most commonly reported effects happen during or right after dosing — dissociation, lightheadedness, drowsiness, and short-lived spikes in blood pressure are all things our clinical staff watch for during the mandatory observation window. A subset of patients also mention nausea or a headache in the hours that follow, though these tend to resolve on their own.
Daily pills work gradually and can take a month or more to show results; Spravato is delivered in-clinic and used together with an oral antidepressant rather than instead of one. IV ketamine hits a related target in the brain but is given through an intravenous line rather than a nasal spray and sits under a different set of federal rules. Which route makes sense — Spravato, ketamine, or sticking with oral medication alone — is a conversation your clinician will walk through with you directly.
That’s exactly the population Spravato was built for. The FDA’s approval specifically covers adults whose depression hasn’t budged after multiple medication trials, so a history of “nothing else has worked” is often the reason patients end up in our office rather than a disqualifying factor.
What you’ll pay depends on how often you’re dosed and how long your course of treatment runs. Because it carries full FDA approval, Spravato tends to see broader insurance support than some alternative treatments, and a number of Nevada plans cover it for patients who meet clinical criteria — our staff can check your specific benefits before you commit to anything.
"*" indicates required fields
